BioInvent Showcases BI-1910 Development at PAGE 2025

BioInvent International AB ( (SE:BINV) ) has issued an announcement.

BioInvent International AB announced the presentation of a poster at the PAGE 2025 meeting in Thessaloniki, Greece, highlighting the early clinical development of its anti-TNFR2 drug candidate, BI-1910. The company successfully developed a population model to characterize the pharmacokinetics and pharmacodynamics of BI-1910, which will aid in dose selection for upcoming Phase 2a studies. These studies, planned for the second half of 2025, will evaluate BI-1910 as a single agent and in combination with pembrolizumab for various tumor types. The announcement underscores BioInvent’s progress in cancer immunotherapy and its potential impact on clinical utility and market potential.

More about BioInvent International AB

BioInvent International AB is a clinical-stage biotech company specializing in the discovery and development of novel, first-in-class immuno-modulatory antibodies for cancer therapy. The company has a proprietary technology platform, F.I.R.S.T™, which identifies targets and the antibodies that bind to them, fueling its clinical development pipeline. BioInvent is involved in multiple clinical programs and generates revenue through research collaborations, license agreements, and antibody production for third parties.

Average Trading Volume: 111,708

Current Market Cap: SEK2.58B

Learn more about BINV stock on TipRanks’ Stock Analysis page.